Showing results (11-20 of 656) with videos related to
Sort By:
Pageof 66
Digestive Diseases (Basel, Switzerland)|January 9, 2013
Environmental factors and their impact on the intestinal microbiota: a role for human disease?Luc Biedermann, Gerhard RoglerPlos One|May 1, 2019
The appearance of joint manifestations in the Swiss inflammatory bowel disease cohortAimee Hiller, Luc Biedermann, Nicolas Fournier, et al.Digestive Diseases (Basel, Switzerland)|December 6, 2017
Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative ProctitisThomas Greuter, Stephan R Vavricka, Luc Biedermann, et al.Digestion|May 24, 2014
Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodiesChristiane Barthel, Luc Biedermann, Pascal Frei, et al.Current Drug Targets|April 30, 2013
Review: new anti-cytokines for IBD: what is in the pipeline?Michael Scharl, Stephan R Vavricka, Gerhard RoglerPlos One|January 26, 2019
Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort StudyNina Roth, Luc Biedermann, Nicolas Fournier, et al.Praxis|January 29, 2014
[Colitis-associated colorectal carcinoma: epidemiology, pathogenesis and early diagnosis]Michael Scharl, Luc Biedermann, Gerhard RoglerDigestive Diseases (Basel, Switzerland)|August 23, 2016
The Search for Causative Environmental Factors in Inflammatory Bowel DiseaseGerhard Rogler, Jonas Zeitz, Luc BiedermannSwiss Medical Weekly|March 23, 2018
New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathwaysGerhard Rogler, Luc Biedermann, Michael ScharlDigestive Diseases (Basel, Switzerland)|February 2, 2017
Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical ImplicationsGerhard Rogler, Luc Biedermann, Michael ScharlPageof 66